ArticleNeuroscience applied2024
GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling.
Article in Neuroscience applied, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.Obesity pillars · 2026Review
- Review
- Effects of GLP-1 analogs on metabolic alterations including male sexual function, hypogonadism and erectile dysfunction: a narrative review.Translational andrology and urology · 2026Review
- The Endogenous Opioid System in Compulsive Eating.Brain sciences · 2026Review
- Sex-Specific and Reproductive Status-Dependent Effects of Liraglutide on Metabolic Disorders Associated with Prediabetes.Antioxidants (Basel, Switzerland) · 2026Article
- SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.Diabetes, obesity & metabolism · 2026Article
- Review
- Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.Psychopharmacology · 2026Article
- The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis.Journal of ovarian research · 2026Article
- Exercise modulates food reward: neurobiological mechanisms and implications for weight management.Frontiers in nutrition · 2026Review
- Lost in translation: why don't dopamine D2 antagonists cure addictions?Journal of psychiatry & neuroscience : JPN · 2026Article
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.International journal of molecular sciences · 2025Review
- Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.Diabetes, obesity & metabolism · 2025Article
- Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights.Medical sciences (Basel, Switzerland) · 2025Review
- Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.Science (New York, N.Y.) · 2025Article
- Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.Neuropharmacology · 2025Review
- Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry.Neuroscience applied · 2025Article
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.Annals of internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semaglutide, a glucagon-like peptide-1 receptor agonist, is an effective drug reducing body weight and decreasing motivation for palatable food. The mechanisms underlying its effects on food reward remain unclear. We aimed to determine the impact of semaglutide on food reward collection and dopamine-neuron activity in the ventral tegmental area (VTA) upon exposure to a cue-induced sucrose delivery task. Pitx3-cre mice were injected with cre-dependent GCaMP6s virus into the VTA, to measure the activity of dopaminergic neurons in the VTA using
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.